[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. James's Hospital, Ireland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":190},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,79,109,139,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100605311","obstructive-sleep-apnoea-and-difficult-asthma-osada-100605311",false,"NCT07160868","Obstructive Sleep Apnoea and Difficult Asthma (OSADA)","Open-label Randomized Controlled Trial Investigating the Relationship Between Obstructive Sleep Apnoea and Difficult Asthma","OSADA","Inclusion Criteria:\n\n* Patients must have a clinical diagnosis of asthma with supportive objective diagnostics including but not limited to, variable airflow obstruction, bronchial-hyper responsiveness and demonstrable eosinophilic inflammation via fractional exhaled nitric oxide or peripheral eosinophilia\n* Patients receiving step 4 or step 5 of 'The Global Initiative for Asthma' (GINA) treatment guidelines will be selected\n* Between the ages of 18 to 90 years of age\n\nExclusion Criteria:\n\n* Patients with previous sleep study investigations\n* Excessive daytime sleepiness; ESS \\>17\n* Previous diagnosis of a sleep disorder\n* Resting hypoxaemia or need for long-term oxygen therapy\n* Inability to provide informed consent","ALL","18 Years","90 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","The OSADA (Obstructive Sleep Apnoea in Difficult Asthma) trial is an open-label, randomized control trial investigating the impact of diagnosing and treating obstructive sleep apnoea (OSA) on a asthma control in patients with difficult-to-control asthma.\n\nParticipants will undergo home-based sleep studies to assess for OSA and are then allocated to one of three arms: 1) Patients with OSA treated with CPAP (intervention group), 2) Patients with OSA not treated for OSA (control group) and 3) Patients without OSA (reference group).\n\nThe primary objective is to evaluate whether treating OSA improves asthma control, symptom burden, and quality of life compared to untreated OSA and to patients without OSA. Secondary outcomes include exacerbation rates, sleep quality, and healthcare utilization.\n\nThis trial aims to clarify the contribution of OSA to poor asthma control and the potential benefits of integrated sleep and respiratory care in this complex population.",[28,29,30],"Asthma (Diagnosis)","OSA - Obstructive Sleep Apnea","CPAP Treatment","RECRUITING","2026-05-20",{"date":34,"type":35},"2026-05-26","ACTUAL",{"date":37,"type":35},"2025-09-01",{"date":39,"type":22},"2026-05-22",{"name":41,"class":42},"St. James's Hospital, Ireland","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":65,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100636151","a-smart-phone-application-to-improve-adoption-of-the-2024-kidney-disease-improving-global-outcomes-kdigo-chronic-kidney-disease-ckd-guidelines-100636151","NCT07561957","A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines","A Smart Phone Application to Improve Adoption of the 2024 KDIGO CKD Guidelines","Inclusion Criteria:\n\n* Adults aged ≥16 years.\n* Diagnosed with CKD stages 1-5.\n* Owns a smartphone and is capable of using mobile applications.\n* Provides informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent due to a neurocognitive impairment.\n* Age 30 years or older\n\nThe study will be conducted in the already established SJH Young Adult Clinic, with anticipated expansion coinciding with the co-location Children's Health Ireland (CHI) on site.","16 Years","30 Years",{"count":21,"type":22},[25],"The goal of this study is to establish whether use of a digital intervention can improve adherence and alignment with the Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) 2024 Guidelines.\n\nA subset of the study will focus on whether the intervention improves outcomes for young adults living with CKD, in the context of the imminent co-location of Children's Health Ireland on the St. James's Hospital campus.\n\nYoung adults with CKD transitioning to adult services are recognised as a high-risk and vulnerable cohort, with many individuals unaware of increased cardiovascular risk and mortality¹². In response, and in the context of the co-location of Children's Health Ireland on the St. James's Hospital site, a young adult nephrology clinic has been established.\n\nThe KDIGO CKD 2024 Guidelines identify transition as a period of increased risk and include recommendations regarding cardiovascular risk factor targets and the use of therapies known to delay CKD progression³.\n\nElectronic communication is a preferred method for accessing health information among many young adults⁴⁵ and aligns with Sláintecare digital health strategies⁶. A recently established, award-winning St. James's Hospital renal smartphone application is currently used by over 3,000 individuals living with CKD.\n\nThe study aims to determine whether use of the application improves adherence to KDIGO guideline recommendations, with the objective of delaying CKD progression and associated complications. The application will support optimisation of care by signposting opportunities for evidence-based interventions (e.g., SGLT2 inhibitors, renin-angiotensin system inhibition) to healthcare providers. The application will also provide participants with tailored recommendations, reminders, educational materials, and collection of patient-reported outcome measures.\n\nDue to the diverse population and range of specialties at St. James's Hospital, the young adult clinic serves distinct subgroups, including individuals with sickle cell anaemia and survivors of cancer and haematological malignancies. These populations will be examined in the context of KDIGO guideline implementation, contributing to a limited international evidence base.\n\nThis research evaluates an intervention designed to improve care for adults living with chronic kidney disease.",[57,58,59,60,61,62,63,64],"Chronic Kidney Disease","Proteinuria","Blood Pressure Control","Congenital Anomalies of the Kidneys and Urinary Tract","Nephrotic Syndrome","Sickle-Cell Nephropathy","Tuberous Sclerosis Complex","Cancer Survivors",[66,67,68,69],"Digital Interventions","Kidney Disease","Paediatric Nephrology","Transitional Nephrology","2026-04-24",{"date":72,"type":35},"2026-05-01",{"date":74,"type":35},"2026-01-14",{"date":76,"type":22},"2027-06-01",{"name":41,"class":42},2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":97,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100617123","phase-2-evaluating-the-impact-of-glp-1-receptor-agonists-with-total-neoadjuvant-therapy-in-rectal-cancer-100617123","NCT07314528","Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer","A Phase II Multi-institutional Randomized Trial Evaluating the Impact of GLP-1 Receptor Agonists in Combination With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* Written informed consent according to local guidelines obtained prior to any study-related activities.\n* Histologically confirmed mismatch repair protein proficient adenocarcinoma of the rectum.\n* BMI ≥25 kg\u002Fm²\n* Radiological confirmed \\>T2, Node positive, Threatened Surgical Margin and\u002For EMVI+ by MRI\n* Imaging available for radiomics analysis\n* Absence of metastatic disease at registration.\n* Adequate renal function is defined as calculated creatinine clearance (CrCl) \\>50ml\u002Fmin.\n* ANC \\> 1.5 cells\u002Fmm3, HGB \\> 8.0 gm\u002Fdl, PLT \\> 150,000\u002Fmm3, total bilirubin ≤ 1.5 x ULN (except in patients with Gilbert's Syndrome who must have total bilirubin ≤ 3.0 x ULN), AST≤ 3 x ULN, ALT ≤ 3 x ULN\n* Able to tolerate medication.\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Received prior chemotherapy or radiotherapy\n* Previous or concurrent active malignancy ≤ 5 years prior to registration, with the exception of non-melanotic skin cancer or carcinoma in situ of any type, or other cancers that the treating investigator does not feel will impact the study objectives.\n* Locally advanced disease T3N+ or T4 disease.\n* Recurrent rectal cancer\n* Metastatic disease at presentation\n* Patients unable to undergo MRI\n* Patients having already received weight-loss intervention (pharmacological or surgical)",{"count":87,"type":22},42,[89],"PHASE2","The goal of this clinical trial is to see if adding a weight loss medication (GLP-1 receptor drug) to patients with an increased BMI receiving treatment for rectal cancer prior to surgery (total neoadjuvant chemoradiotherapy) improves cancer outcomes. The main questions it aims to answer is\n\n1. Does the drug increase weight loss in rectal cancer patients with a high BMI\n2. Does the drug improve response rates to chemotherapy and radiotherapy\n3. Does the drug improve survival outcomes and if cancer returns\n\nResearchers will compare this drug in one group against a group of patients receiving preoperative total neoadjuvant chemoradiotherapy without the drug\n\nPatients will be required to\n\n1\\) take the GLP-1 receptor agonist drug during TNT or just having TNT alone as per standard hospital protocols\n\nBody weight will be measured at three predefined time points:\n\n1. Baseline: Prior to initiation of semaglutide or TNT\n2. Pre-TNT: Start of TNT (for the intervention arm, this is 4 weeks after semaglutide initiation)\n3. Post-TNT: Within 7 days following completion of TNT and prior to definitive surgery\n\nPatients will complete their treatment and go on to have surgery as per standard methods for treating rectal cancer",[92,93,94,95,96],"Rectal Cancer Patients","Obesity &Amp; Overweight","Locally Advanced Rectal Cancer (LARC)","Total Neoadjuvant Therapy","GLP-1",[98,95,99],"Locally Advanced Rectal Cancer","GLP-1 Receptor Agonist","NOT_YET_RECRUITING","2025-12-17",{"date":103,"type":35},"2026-01-02",{"date":105,"type":22},"2026-04",{"date":107,"type":22},"2028-09",{"name":41,"class":42},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":43},"100558357","her2-status-in-esophagogastric-adenocarcinoma-and-its-associations-with-patients-clinicopathological-outcomes-100558357","NCT06550063","HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes","HERA","Inclusion Criteria:\n\n* Patients with newly diagnosed EGA from 2000 to April 2024 across all stages of disease\n* Primary tumour HER2 status tested as routine in all patients with EGA\n* Patients aged 18 years or over\n\nExclusion Criteria:\n\n\\- Patients with esophageal squamous cell carcinoma",{"count":117,"type":22},2188,"OBSERVATIONAL","Targeted therapies offer promise to improve oncologic outcomes in esophagogastric adenocarcinoma (EGA). The landmark 'Trastuzumab for gastric cancer (ToGA)' trial established the therapeutic value of Human Epidermal Growth Factor Receptor 2 (HER2) directed therapy in advanced gastric and esophagogastric junction adenocarcinoma, setting a standard of care. Further studies, such as DESTINY-gastric01 and DESTINY-gastric02, have demonstrated the efficacy of antibody-drug conjugates (ADCs) targeting HER2-positive gastric and junctional tumours. The use of HER2-directed therapies in the curative intent setting has more recently been evaluated with favourable outcomes in phase II studies. However, data regarding the prevalence and prognostic significance of HER2 overexpression among patients undergoing treatment with curative intent are limited. Furthermore, few studies have evaluated the clinical significance of intratumoural and tumour-metastatic heterogeneity of HER2 expression, and the finding of HER2-low, in this context, which may have important implications for implementation of neoadjuvant targeted therapies in future. While limited single centre series have evaluated the clinicopathologic significance of HER2 status in EGA, no previous international multicentre study of this nature has been reported.\n\nThe goal of this international, multi-center, retrospective observational study is to elucidate the prevalence and clinical significance of HER2 expression in patients with EGA across different regions globally. The study also aims to assess the clinical significance of HER2 heterogeneity in a large, international cohort of patients with EGA, and its association with clinicopathological outcomes in patients with advanced and recurrent disease.",[121,122,123,124],"Esophagus Cancer","Gastric Cancer","HER2-positive Cancer","HER2-low Cancer",[126,127,128,129,130],"Esophageal cancer","Gastric cancer","HER2-positive cancer","HER2-low cancer","Targeted treatment","2024-08-12",{"date":133,"type":35},"2024-08-13",{"date":135,"type":22},"2024-08-20",{"date":137,"type":22},"2025-08-31",{"name":41,"class":42},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100529781","rada16-for-reducing-drain-output-trajectory-following-neck-dissection-100529781","NCT06178237","RADA16 for Reducing Drain Output Trajectory Following Neck Dissection","ROUND","Inclusion Criteria:\n\n* Patients with head and neck cancer (including thyroid, cutaneous, \\& mucosal primaries) for which a neck dissection is indicated as part of treatment.\n* Over 18 years of age.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Patients unable to satisfy all the above listed inclusion criteria.","100 Years",{"count":148,"type":22},208,[25],"This will be a prospective single-blind randomised controlled trial to evaluate if the use of a medical device named Purabond, a haemostatic agent already CE marked for use in Ireland, can reduce the occurrence of seroma, a complication related to but distinct from haematoma, following neck dissection surgery. Patients undergoing neck dissection surgery will be randomised either to standard post-operative care following neck dissection or to standard post-operative care and Purabond. Drains are placed routinely following surgery of this type and their removal is dictated by the volume of fluid produced per day - it is hypothesised that Purabond will reduce the volume of fluid produced and thereby facilitate earlier drain removal.",[152],"Head and Neck Cancer",[154],"seroma","2023-12-11",{"date":157,"type":35},"2023-12-20",{"date":159,"type":22},"2024-03",{"date":161,"type":22},"2026-06",{"name":41,"class":42},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100523571","phase-3-neoadjuvant-chemoradiotherapy-versus-total-neoadjuvant-therapy-in-the-treatment-of-t3-rectal-cancer-100523571","NCT06097416","Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer","A Phase III, Multi-institutional Randomised Trial Comparing Neoadjuvant Chemoradiotherapy (NARCT) and Total Neoadjuvant Therapy (TNT) in Patients With T3 (a\u002Fb\u002Fc) Rectal Cancer","Patients are eligible to be included in the study only if they meet all of the following criteria:\n\n1. Written informed consent must be given according to ICH\u002FGCP and national\u002Flocal regulations and be obtained prior to any study-related procedures.\n2. Histologically or cytologically confirmed surgically resectable adenocarcinoma of the rectum.\n3. Clinical stage II (T3, N-) \\\\\n4. Absence of metastatic disease\n5. Eastern Co-operative Oncology Group (ECOG) performance status \\> 2.\n6. Age \\> to 18.\n7. Estimated life expectancy ≥ 12 months.\n8. No active infections requiring systemic antibiotic treatment (oral antibiotics are acceptable at the discretion of the treating physician).\n9. Measurable disease, as defined by RECIST Version 1.1\n10. Adequate haematological, hepatic, and renal function defined as:\n\n    a. Renal: i. Calculated creatinine clearance (CrCl) \\> 50ml\u002Fmin (see Appendix G)\n\n    b. Liver function tests: i. Total Bilirubin \\\u003C 1.5 ULN\n\n    (OR \\\u003C 3 x ULN (\\\u003C Grade 2) in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline.) ii. ALT and AST \\\u003C 2.5 x ULN (\\\u003C 5 x ULN with liver involvement of their cancer) iii. Alkaline Phosphatase \\\u003C 2.5 x ULN (\\\u003C 5 x ULN with liver involvement of their cancer)\n\n    c. Haematology: i. Haemoglobin \\> 9 g\u002FdL (\\\u003C Grade 1) ii. Absolute neutrophil count \\> 1.5 x 109\u002FL iii. Platelet count \\> 100 x109\u002FL (≤ Grade 1)\n11. Normal thyroid function defined as a TSH within normal local institutional range\n12. Able to swallow and retain oral medication\n13. Women of childbearing potential (WOCBP) and male patients with partners of childbearing potential; agree to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraception measures during the treatment period. For women, highly effective contraception should be used, for X months after last dose of (INSERT AGENT). For men, highly effective contraception should be used, for X months after (INSERT AGENT). (Highly effective contraception is defined in the study as methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include:\n\n    i. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal).\n\n    ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable and implantable).\n\n    iii. Intrauterine device (IUD). iv. Intrauterine hormone-releasing system (IUS). v. Bilateral tubal occlusion. vi. Successfully vasectomised partner. vii. Sexual abstinence.)\n14. Women of childbearing potential must have pregnancy excluded by urine or serum beta-HCG testing within 7 days prior to registration.\n\nExclusion criteria:\n\nPatients who meet any of the following criteria at the time of screening will be excluded from study registration:\n\n1. Received prior chemotherapy for local or metastatic disease.\n2. Locally advanced rectal cancer; \\>T3, Nodal disease\n3. Primary unresectable rectal cancer. A tumour is considered unresectable when invading adjacent organs and an en bloc resection will not achieve negative margins.\n4. Received prior pelvic radiotherapy.\n5. Patients unable to undergo MRI.\n6. Previous or concurrent active malignancy ≤ 5 years prior to registration with the exception of non-melanotic skin cancer or carcinoma in situ of any type, or other cancers that the treating Investigator does not feel will impact the study objectives.\n7. Screening electrocardiogram (ECG) with evidence of:\n\n   1. QT prolongation (QTc \\> 450ms in males and \\> 470ms in females)\n   2. Clinically significant cardiac arrhythmias, complete left bundle branch block, high atrioventricular AV block (e.g. bi-vascular block , Mobitz type II and third degree AV block\n   3. Other severe cardiac dysfunction\n\n   (ECG must be assessed for all patients within 14 days prior to registration).\n8. Clinically significant cardiovascular disease including:\n\n   1. Cerebrovascular accident within 6 months prior to registration\n   2. Myocardial infarction within 6 months prior to registration\n   3. Uncontrolled angina\n   4. Uncontrolled or poorly controlled arterial hypertension (i.e. BP \\>150\u002F90mmHg under treatment with at a maximum three antihypertensive drugs)\n   5. Clinically significant valvular disease\n   6. Congestive Heart Failure (NYHA \\> Class 2 (See Appendix E)\n   7. Known family history of idiopathic cardiac arrest or sudden death whereby a cardiac cause cannot be excluded\n   8. Known history or family history of Brugada Syndrome.\n9. Known pulmonary compromise, as determined by the treating investigator, resulting from intercurrent pulmonary illness, but not limited to, any pulmonary disorder (e.g. severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease.\n10. Creatinine level \\>1.5x ULN\n11. Patients with a history of any arterial thromobotic event within the past 6 months. This includes angina (stable or unstable), MI, TIA or CVA.\n12. Patients with a history of venous thrombotic episodes such as DVT, PE occurring more than 6 months prior to enrolment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Similarly, patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.\n13. Pregnant or nursing women.\n14. Concurrent treatment with any other investigational agents within 30 days prior to registration.\n15. Any psychological, physical, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; (those conditions should be discussed with the patient before registration in the trial).\n16. Unable or unwilling to discontinue (and substitute if necessary) use of prohibited medications for at least 30 days prior to and for the duration of study treatment (see section 7.5 for a description of prohibited medications).",{"count":171,"type":22},100,[173],"PHASE3","The gold standard treatment for locally advanced, non-metastatic rectal cancer includes neoadjuvant chemoradiotherapy (NACRT), total mesorectal excision (TME) and adjuvant chemotherapy (AC). The primary goal of treatment is to achieve local disease control, reduce tumour volume and minimise the risk of distant metastases. While this multimodal treatment approach has offered improvements in local control and sphincter preservation, it has had little effect on distant recurrence and overall survival. We aim to compare NACRT and TME using the following endpoints:\n\nPrimary --\\>To compare the effects neoadjuvant chemoradiotherapy versus total neoadjuvant therapy (TNT) for T3 rectal cancer on overall survival.\n\nSecondary --\\> To compare the effects neoadjuvant chemoradiotherapy (NARCT) and total neoadjuvant therapy (TNT) for cT3 rectal cancer on clinical outcomes:\n\n* Clinical complete response (cCR)\n* Pathological complete response (pCR)\n* Disease-free survival (DFS)\n* Organ preservation\n* Overall morbidity \u002F mortality\n* Treatment-related morbidity \u002F mortality\n* Peri-operative outcomes",[176],"Rectal Cancer",[178,179,180,181],"Rectal cancer","Neoadjuvant chemoradiotherapy","Total neoadjuvant therapy","Survival","2023-10-24",{"date":184,"type":35},"2023-10-25",{"date":186,"type":22},"2024-10",{"date":188,"type":22},"2030-10",{"name":41,"class":42},""]